Brief Report: The Genetic Profile of Rheumatoid Factor–Positive Polyarticular Juvenile Idiopathic Arthritis Resembles That of Adult Rheumatoid Arthritis

Objective Juvenile idiopathic arthritis (JIA) comprises 7 heterogeneous categories of chronic childhood arthritides. Approximately 5% of children with JIA have rheumatoid factor (RF)–positive arthritis, which phenotypically resembles adult rheumatoid arthritis (RA). Our objective was to compare and...

Full description

Saved in:
Bibliographic Details
Published inArthritis & rheumatology (Hoboken, N.J.) Vol. 70; no. 6; pp. 957 - 962
Main Authors Hinks, Anne, Marion, Miranda C., Cobb, Joanna, Comeau, Mary E., Sudman, Marc, Ainsworth, Hannah C., Bowes, John, Becker, Mara L., Bohnsack, John F., Haas, Johannes‐Peter, Lovell, Daniel J., Mellins, Elizabeth D., Nelson, J. Lee, Nordal, Ellen, Punaro, Marilynn, Reed, Ann M., Rose, Carlos D., Rosenberg, Alan M., Rygg, Marite, Smith, Samantha L., Stevens, Anne M., Videm, Vibeke, Wallace, Carol A., Wedderburn, Lucy R., Yarwood, Annie, Yeung, Rae S. M., Langefeld, Carl D., Thompson, Susan D., Thomson, Wendy, Prahalad, Sampath
Format Journal Article
LanguageEnglish
Published United States Wiley Subscription Services, Inc 01.06.2018
Wiley
John Wiley and Sons Inc
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Objective Juvenile idiopathic arthritis (JIA) comprises 7 heterogeneous categories of chronic childhood arthritides. Approximately 5% of children with JIA have rheumatoid factor (RF)–positive arthritis, which phenotypically resembles adult rheumatoid arthritis (RA). Our objective was to compare and contrast the genetics of RF‐positive polyarticular JIA with those of RA and selected other JIA categories, to more fully understand the pathophysiologic relationships of inflammatory arthropathies. Methods Patients with RF‐positive polyarticular JIA (n = 340) and controls (n = 14,412) were genotyped using the Immunochip array. Single‐nucleotide polymorphisms were tested for association using a logistic regression model adjusting for admixture proportions. We calculated weighted genetic risk scores (wGRS) of reported RA and JIA risk loci, and we compared the ability of these wGRS to predict RF‐positive polyarticular JIA. Results As expected, the HLA region was strongly associated with RF‐positive polyarticular JIA (P = 5.51 × 10−31). Nineteen of 44 RA risk loci and 6 of 27 oligoarticular/RF‐negative polyarticular JIA risk loci were associated with RF‐positive polyarticular JIA (P < 0.05). The RA wGRS predicted RF‐positive polyarticular JIA (area under the curve [AUC] 0.71) better than did the oligoarticular/RF‐negative polyarticular JIA wGRS (AUC 0.59). The genetic profile of patients with RF‐positive polyarticular JIA was more similar to that of RA patients with age at onset 16–29 years than to that of RA patients with age at onset ≥70 years. Conclusion RF‐positive polyarticular JIA is genetically more similar to adult RA than to the most common JIA categories and thus appears to be a childhood‐onset presentation of autoantibody‐positive RA. These findings suggest common disease mechanisms, which could lead to novel therapeutic targets and shared treatment strategies.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Arthritis & Rheumatology
The contents herein are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health, other funders, the National Health Service, the National Institute for Health Research, or the Department of Health.
Dr. Mellins has received consulting fees from Novartis (less than $10,000). Dr. Stevens owns stock or stock options in Amgen. Dr. Prahalad has received consulting fees from Novartis (less than $10,000).
Dr. Hinks and Ms Marion contributed equally to this work. Drs. Langefeld, Thompson, Thomson, and Prahalad contributed equally to this work.
Genotyping of the US juvenile idiopathic arthritis (JIA), German JIA, and respective control collections was supported by the NIH (Center for Scientific Review [CSR] grants RC1‐AR‐058587 and U01‐AI‐067150S1). Patient recruitment and DNA preparation in the US were largely funded by the NIH (CSR grants N01‐AR‐42272, P01‐AR‐048929, P30‐AR‐473639, K23‐AR‐50177, and R01‐AR‐060893), with contributions from the Rheumatology Research Foundation, the Arthritis Foundation, the Val A. Browning Charitable Foundation (Salt Lake City, UT), and the Marcus Foundation, Inc. (Atlanta, GA). The Federal Ministry of Education and Research, Germany supported patient recruitment and sample preparation in Germany (BMBF grants 01GM0907 and 01 ZZ 0403). Support for computing resources and data analysis was provided by the Wake Forest School of Medicine Center for Public Health Genomics and the NIH (CSR grant R01‐AR‐057106). Genotyping of the UK JIA case samples was supported by Arthritis Research UK (grant 20385). Collection of some of the samples used in this study was supported by the NIHR Biomedical Research Centre. The Arthritis Research UK Centre for Genetics and Genomics laboratory is supported by the Manchester Academic Health Sciences Centre. The Childhood Arthritis Prospective Study was funded by Arthritis Research UK (grant 20542). The Childhood Arthritis Response to Medication Study was funded by Sparks UK (grant 08ICH09), Arthritis Research UK (grant 20164), and the Medical Research Council (grant MR/M004600/1) and supported by the NIHR Biomedical Research Centres at Great Ormond Street Hospital for Children NHS Foundation Trust, University College London Hospitals Trust, and the NIHR Clinical Research Network. Patient recruitment and DNA preparation in Canada was supported by the Canadian Institutes of Health Research (grant FRN‐82517), the Canadian Arthritis Society, and the Canadian Arthritis Network. The Nord‐Trøndelag Health (HUNT) Study, which contributed control samples, is a collaboration between the HUNT Research Centre (Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology), Nord‐Trøndelag County Council, Central Norway Health Authority, and the Norwegian Institute of Public Health and was funded by the Liaison Committee between the Central Norway Regional Health Authority and the Norwegian University of Science and Technology. Sample recruitment was supported in part by the NIH (National Institute of Arthritis and Musculoskeletal and Skin Diseases grants N01‐AR‐62277 and AR‐053483, National Institute of General Medical Sciences grant GM‐103510, and National Institute of Allergy and Infectious Diseases grant AI‐082714) and by the Texas Scottish Rite Hospital for Children (grant 1296353). Genotyping of control samples was supported, in part, by the Juvenile Diabetes Research Foundation International and the NIH (CSR grant U01‐DK‐062418).
ISSN:2326-5191
2326-5205
2326-5205
DOI:10.1002/art.40443